Patient
SITE013-0027
enrolled Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE013 (USA) (Dr. Clarke)
consented 2025-09-22
Adverse events
5
Serious AEs
2
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 5
Grade 3 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-01-08 (study day 279); relationship: NOT RELATED; serious criteria: hospitalization
Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-11-18 (study day 228); relationship: not assessed; serious criteria: hospitalization
Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-08-22 (study day 140); relationship: not assessed
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-07-08 (study day 95); relationship: not assessed
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-07-01 (study day 88); relationship: not assessed
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.